- Home
- BEAT vs CBUS Comparison
BEAT vs CBUS Comparison
Compare BEAT & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAT | CBUS |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Agricultural Chemicals |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 69.9M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BEAT | CBUS |
|---|---|---|
| Price | $2.27 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.75 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 30.8M | 168.2K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,794,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $109.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $1.09 |
| 52 Week High | $3.48 | $4.24 |
Technical Indicators
Market Signals| Indicator | BEAT | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 74.82 | 57.01 |
| Support Level | $0.66 | $1.50 |
| Resistance Level | $2.82 | $1.75 |
| Average True Range (ATR) | 0.26 | 0.14 |
| MACD | 0.18 | 0.04 |
| Stochastic Oscillator | 75.67 | 69.23 |
Price Performance
Historical ComparisonAbout BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.